Biodesix, Inc. (BDSX)
| Market Cap | 704.67M |
| Revenue (ttm) | 21.55M |
| Net Income (ttm) | -34.10M |
| Shares Out | 26.25M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $27.17 |
| Previous Close | $27.59 |
| Change ($) | -0.42 |
| Change (%) | -1.52% |
| Day's Open | 27.53 |
| Day's Range | 25.18 - 28.84 |
| Day's Volume | 144,015 |
| 52-Week Range | 10.89 - 31.21 |
NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX) today announced an agreement with HiberCell, a biotechnology company developing novel therapeutics for cancer relapse ...
NEW YORK and BOULDER, Colo., Jan. 13, 2021 /PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with...
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...
Biodesix has gone public in an offering which was not well-received by the market. Lack of growth and steep losses make investors rightfully cautious based on the conditions as they are today.
About BDSX
Biodesix operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests provide physicians with timely results to facilitate treatment decisions. It also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutica... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 28, 2020 |
| CEO Scott Hutton | Employees 186 |
| Stock Exchange NASDAQ | Ticker Symbol BDSX |
Financial Performance
In 2019, Biodesix's revenue was $24.55 million, an increase of 20.16% compared to the previous year's $20.43 million. Losses were -$30.73 million, 17.4% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for Biodesix stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is a decrease of -15.35% from the latest price.